--- title: "Guangzhou Baiyunshan Pharma Sets Vote on New Three-Year Board Line-Up" type: "News" locale: "en" url: "https://longbridge.com/en/news/285572574.md" description: "Guangzhou Baiyunshan Pharmaceutical Holdings Company (HK:0874) announced that its ninth board's term is ending, and shareholders will vote on a new tenth board at the 2025 annual general meeting. The proposed board will consist of eleven directors, including ten non-employee representatives and one employee representative. The company has nominated ten candidates, focusing on governance continuity and compliance with Hong Kong listing rules. If approved, each director will serve a three-year term. The company operates in the pharmaceutical industry, manufacturing and distributing medicines and healthcare products." datetime: "2026-05-07T14:19:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285572574.md) - [en](https://longbridge.com/en/news/285572574.md) - [zh-HK](https://longbridge.com/zh-HK/news/285572574.md) --- # Guangzhou Baiyunshan Pharma Sets Vote on New Three-Year Board Line-Up ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has shared an update. Guangzhou Baiyunshan Pharmaceutical Holdings has announced that the term of its ninth board is ending and that shareholders will vote on a new, tenth board at the 2025 annual general meeting. The proposed board will comprise eleven directors, including ten non‑employee representatives and one employee representative elected separately by staff. The company has nominated ten director candidates, combining reappointments of existing executive and independent non‑executive directors with several new nominees. It emphasized that candidates meet Hong Kong listing rules on independence and disclosure, and, if approved, each director will serve a three‑year term, underscoring a focus on governance continuity and regulatory compliance. **More about Guangzhou Baiyunshan Pharmaceutical Holdings Company** Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a Chinese joint stock company listed in Hong Kong that operates in the pharmaceutical industry. The group focuses on manufacturing and distributing medicines and related healthcare products, serving domestic and international markets through its diversified portfolio and established brands. **Average Trading Volume:** 1,261,587 **Technical Sentiment Signal:** Sell **Current Market Cap:** HK$40.41B For a thorough assessment of 0874 stock, go to TipRanks’ Stock Analysis page. ### Related Stocks - [00874.HK](https://longbridge.com/en/quote/00874.HK.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [159929.CN](https://longbridge.com/en/quote/159929.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [516610.CN](https://longbridge.com/en/quote/516610.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [600332.CN](https://longbridge.com/en/quote/600332.CN.md) ## Related News & Research - [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md) - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations](https://longbridge.com/en/news/286197909.md) - [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md) - [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)